Eli Lilly Says New Long-Term Data Showed Omvoh Delivered Durable Efficacy Through Three Years In Adults With Moderately To Severely Active Crohn's Disease; Landmark VIVID-2 Data Showed More Than 90% Of Patients Who Achieved Steroid-Free Remission At One Year Maintained Steroid-Free Control Through Three Years

Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years 

Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory 

Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's disease

INDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm. Additional data presented from the Phase 3 VIVID-1 (Crohn's disease) and LUCENT-3 (UC) clinical trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease (IBD).2,3 Omvoh is the first and only IL-23p19 inhibitor to show strong and durable efficacy over four years in UC and three years in Crohn's disease, with proven reduction of disease complications.